EU approves first SGLT-2-class diabetes drug
The major players on the lucrative market for diabetes medicine face new competition from the first ever approved product in the newest class of drugs against type 2 diabetes – the so-called SGLT-2 drugs, as Astrazeneca and Bristol-Myers Squibb have had the pill Forxiga, which works independently of traditional insulin, approved for the European markets.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app